$3.61
▲ +2.5% Today
as of Jul 22, 16:45 ET
Last 30 days
Recent Press Releases & News
Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date
Anixa Biosciences secures Korean patent for breast cancer vaccine
Anixa Biosciences Granted Korean Patent for Breast Cancer Vaccine
Overview
52-week range
$2.44
$5.46
39% of range
Avg surprise (last 1)
+10.0%
Avg reaction (last 1)
+1.6%
100% positive
Latest IV / EM
36%
EM ±8.3% · $3 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Sat Jan 31, 2026 | Jan 2026 | $-0.08 | — | — | — | — | financials |
| Thu Jul 31, 2025 | Jul 2025 | $-0.07 | — | — | — | — | financials |
| Wed May 28, 2025 | Apr/2025 | $-0.09 | $-0.10 | +10.0% | — | +1.6% | earnings |
| Fri Jan 31, 2025 | Jan 2025 | $-0.10 | — | — | — | — | financials |
| Wed Jul 31, 2024 | Jul 2024 | $-0.10 | — | — | — | — | financials |
| Tue Apr 30, 2024 | Apr 2024 | $-0.10 | — | — | — | — | financials |
| Wed Jan 31, 2024 | Jan 2024 | $-0.10 | — | — | — | — | financials |
| Mon Jul 31, 2023 | Jul 2023 | $-0.08 | — | — | — | — | financials |
| Sun Apr 30, 2023 | Apr 2023 | $-0.07 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-3M | — | $-2M | $-3M | $-3M | — | $-4M | $-3M |
| Net income | $-3M | — | $-2M | $-3M | $-3M | — | $-3M | $-3M |
| EPS (diluted) | $-0.08 | — | $-0.07 | $-0.09 | $-0.10 | — | $-0.10 | $-0.10 |
Balance sheet (quarterly)
| Metric | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $2M | $1M | $1M | $2M | $1M | $1M | $1M | $995,000 |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $15M | $16M | $17M | $17M | $19M | $21M | $23M | $24M |
| Total assets | $15M | $16M | $18M | $17M | $19M | $22M | $23M | $24M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $1M | $2M | $2M | $2M | $2M | $3M | $2M | $2M |
| Total equity | $15M | $15M | $17M | $16M | $18M | $20M | $22M | $24M |